AbbVie’s Stalling Tactics On Humira Pay Off – In More Ways Than One

 
• By Michael McCaughan

A US House hearing focused on long-standing criticism of AbbVie for its ability to delay biosimilar competition for Humira. AbbVie was also able to delay the hearing, and that also seemed to work out well for the company.

Richard Gonzalez may expect delays. Photo illustration/Alamy, Getty
Richard Gonzalez may actually enjoy this kind of traffic. • Source: photo illustration/Alamy, Getty

More from Pricing Debate

More from Market Access